Pembroke Pines, FL (PRWEB) January 15, 2009
NextWave Research announces the publication of our "Medical Device Outlook for 2009" highlighting the shift to lower-technology with constant demand during the difficult economy.
Analyst John M. Putnam, CFA views the greatest risk to be unemployment with loss of medical insurance and healthcare providers forced to limit operations. Mr. Putnam states, "Given these constraints, which could last through most of 2009, we favor companies whose products are lower tech and in constant demand regardless of the economy, such as point-of-care diagnostics, minimally invasive surgical instruments and general care products such as syringes, catheters, sutures, blood products, etc."
He further believes that elective cosmetic procedures such as breast implants and plastic surgery procedures are discretionary and can be postponed making them less attractive investments in the current environment.
Some companies mentioned are Johnson & Johnson (NYSE: JNJ), Abbott Labs (NYSE: ABT), Baxter (NYSE: BAX), Becton Dickinson (NYSE: BDX), Haemonetics (NYSE: HAE), NuVasive (Nasdaq: NUVA), Medtronic (NYSE: MDT) and St. Jude (NYSE: STJ).
NextWave Research founder, Stephen M. Dunn states "Now more than ever, investors need to not only rebalance their portfolio, but to also rebalance the themes underpinning their investments. 2009 represents a time to update strategies in light of widespread financial difficulties."
Interested readers can access all of NextWave Research's analysis free-of-charge at http://www.NextWaveResearch.com
About NextWave Research:
NextWave Research was created to address the dearth of professional Wall Street research coverage for quality small-cap companies. We believe that quality companies who choose to sponsor research analyst coverage provide a desperately needed service to both individual and institutional investors with reports and commentary freely available to all. We Don't Get Paid to Like Companies-We Get Paid by Companies We LikeTM
Stephen M. Dunn